- Award ID
- W911SR23F0049
- Sub-agency / office
- Department of the Army
- Award amount
- $49,500,000
- Period of performance
- Feb 17, 2023 – Feb 16, 2028
- NAICS
- 541712 — Research and Development in the Physical, Engineering, and Life Sciences
- Place of performance
- COLUMBUS, OH, 432012696, USA
- Competition
- FULL AND OPEN COMPETITION · 1 offers
- Pricing
- COST PLUS FIXED FEE
- Financial breakdown
- Current value $49,500,000 · Obligated $23,622,221 · Potential value $49,500,000 · Latest action obligation $596,715
- Parent award
- GS00Q14OADU402
Most recent · Modification P00029 · Jun 29, 2026 · $596,715 action obligation · THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002, CLIN 0003, AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. · W911SR23F0049
Modification P00028 · Jun 10, 2026 · $-321,000 action obligation · THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002, CLIN 0003, AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. · W911SR23F0049
Modification P00027 · Jan 30, 2026 · $1,133,401 action obligation · THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002, CLIN 0003, AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. · W911SR23F0049
Modification P00026 · Jan 21, 2026 · $-252,102 action obligation · THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002, CLIN 0003, AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. · W911SR23F0049
Modification P00025 · Dec 16, 2025 · $676,869 action obligation · THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002, CLIN 0003, AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. · W911SR23F0049
Modification P00024 · Sep 26, 2025 · $957,541 action obligation · THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002 AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. · W911SR23F0049
Modification P00023 · Sep 18, 2025 · $333,888 action obligation · THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002 AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. · W911SR23F0049
Modification P00022 · Aug 15, 2025 · $2,261,474 action obligation · THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002 AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. · W911SR23F0049
Modification P00021 · Jul 30, 2025 · $3,259,512 action obligation · THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002 AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. · W911SR23F0049
Modification P00020 · Apr 28, 2025 · $2,875,114 action obligation · TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. · W911SR23F0049
Modification P00019 · Mar 14, 2025 · $20,000 action obligation · TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. · W911SR23F0049
Modification P00018 · Feb 4, 2025 · $1,504,922 action obligation · TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. · W911SR23F0049
Modification P00017 · Dec 11, 2024 · $631,579 action obligation · TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. · W911SR23F0049
Modification P00016 · Nov 6, 2024 · $754,357 action obligation · TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. · W911SR23F0049
Modification P00015 · Sep 3, 2024 · $1,065,947 action obligation · TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. · W911SR23F0049
Modification P00014 · Jun 6, 2024 · $0 action obligation · TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. · W911SR23F0049
Modification P00013 · Jun 4, 2024 · $0 action obligation · TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. · W911SR23F0049
Modification P00012 · May 23, 2024 · $1,773,527 action obligation · TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. · W911SR23F0049
Modification P00011 · Apr 5, 2024 · $236,822 action obligation · TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. · W911SR23F0049
Modification P00010 · Feb 27, 2024 · $946,073 action obligation · TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. · W911SR23F0049
Modification P00009 · Jan 11, 2024 · $201,230 action obligation · NON-CLNICAL STUDIES · W911SR23F0049
Modification P00008 · Jan 9, 2024 · $517,055 action obligation · NON-CLNICAL STUDIES · W911SR23F0049
Modification P00007 · Nov 16, 2023 · $262,865 action obligation · COUNTERING EMERGING THREATS RAPID ACQUISITION AND INVESTIGATION OF DRUGS FOR REPURPOSING DEVELOPMENT SUPPORT STUDIES. · W911SR23F0049
Modification P00006 · Aug 29, 2023 · $282,236 action obligation · NON-CLNICAL STUDIES · W911SR23F0049
Modification P00005 · Aug 15, 2023 · $460,891 action obligation · NON-CLNICAL STUDIES · W911SR23F0049